• What is CMT?
    • About CMT
    • Type1
      • What is CMT1A?
      • What is CMT1B?
      • What is CMT1E?
      • What is HNPP?
    • Type2
      • What is CMT2A?
    • Type4
      • What is SORD?
    • TypeX
      • Understanding CMT1X/CMTX1 and GJB1
    • —-
    • Watch Our Video Series
    • Learn About Treatments in Development
  • Research
    • Research Approach
    • Research Projects We Fund
    • Research Pipeline
    • Gene Therapy
    • Clinical Trials
    • —-
    • Apply for Funding
    • Young Researchers Innovation Grant
  • News & Stories
    • News
    • CMT Stories
  • Take Action
  • About Us
    • Who We Are
    • Board of Directors
    • Research Advisory Council
    • Scientific Advisory Board
    • Research Foundation Staff
    • Events
    • Financials
    • Contact Us
    • Global CMT Research Convention
  • Donate
Update from the Novartis CMT1A Development Team

Update from the Novartis CMT1A Development Team

Oct 29, 2023 | About CMT, Drug Development

As you know, the CMT Research Foundation is proud to have introduced DTx leadership to Charcot-Marie-Tooth disease in 2019. We funded their first work in CMT to demonstrate the FALCON platform’s potential to deliver a drug to the Schwann cells. And from there,...
CMT Research Foundation Launches Research Advisory Committee of Renowned Scientific Experts

CMT Research Foundation Launches Research Advisory Committee of Renowned Scientific Experts

Oct 18, 2023 | Foundation News, Research News

ATLANTA (October 18, 2023) The CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced the formation of a Research Advisory Committee (RAC) consisting of: Dr. William...
Another Asset with Potential to Treat Charcot-Marie-Tooth has been Acquired by Pharma

Another Asset with Potential to Treat Charcot-Marie-Tooth has been Acquired by Pharma

Sep 26, 2023 | CMT Research Updates, CMTRF Funded Research, Drug Development, Research News

An asset that is being tested in CMT4B1 underwritten by the CMT Research Foundation has been licensed by AcuraStem to Takeda for approximately $580 million. The exclusive, worldwide license will enable Takeda to develop and commercialize AcuraStem’s PIKFYVE...
The CMT Research Foundation Launches Annual CMT Action Month with Special September of Events

The CMT Research Foundation Launches Annual CMT Action Month with Special September of Events

Sep 1, 2023 | Foundation News

To mark CMT Action Month this September, the CMT Research Foundation (CMTRF) today launched a month-long lineup of events, bringing together artists, advocates, and the CMT community from across the U.S. The series of events aim to raise awareness and critical funds...
W. David Arnold, MD Joins CMT Research Foundation Scientific Advisory Board

W. David Arnold, MD Joins CMT Research Foundation Scientific Advisory Board

Aug 14, 2023 | Foundation News

ATLANTA (August 14, 2023) CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced that Dr. W. David (Dave) Arnold has joined the Foundation’s Scientific Advisory...
« Older Entries
Next Entries »

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Foundation News
  • Life with CMT
  • Research News

Help us find a cure.

Donate Now
Donate Now

Help us find a cure.

NEWSLETTER SIGNUP

Stay up to date on new CMT research, treatments and clinical trials



Address

4062 Peachtree Road
Suite A209
Atlanta, GA 30319



Phone Number

404.806.7180



EMAIL

[email protected]

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2025 CMT Research Foundation | Privacy Policy

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}